Prestige Consumer Healthcare Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter ended December 31, 2022, with comparative results for the three and nine months ended December 31, 2021. Fiscal year ends March 31. Amounts below are in U.S. dollars; financial statement figures are generally in millions unless stated otherwise.
Business context and results
Prestige develops, markets, manufactures and distributes over-the-counter healthcare products in North America and international markets. Its reportable segments are North American OTC Healthcare and International OTC Healthcare.
| Metric | Three months ended Dec. 31, 2022 | Year-over-year | Nine months ended Dec. 31, 2022 | Year-over-year |
|---|---|---|---|---|
| Total revenue | $275.5 | +0.4% | $841.9 | +2.7% |
| Gross profit / gross margin | $150.4 / 54.6% | $155.1 / 56.5% | $471.5 / 56.0% | $471.8 / 57.5% |
| Operating income | $87.2 | +5.6% | $258.6 | +2.4% |
| Net income | $52.0 | +3.5% | $158.2 | +3.2% |
| Diluted EPS | $1.04 | vs. $0.99 | $3.14 | vs. $3.02 |
Quarterly North American revenue declined 1.6% to $236.9 million, led by lower Women’s Health and Eye & Ear sales; International revenue rose 15.0% to $38.6 million. For the nine-month period, North American revenue decreased 0.5% to $731.5 million and International revenue increased 30.0% to $110.4 million, principally reflecting strength in Australia, including Hydralyte. Cough & Cold increased in North America, while Women’s Health declined.
Financial position, cash flow and capital
- Cash and liquidity: Cash was $86.4 million at December 31, 2022, up from $27.2 million at March 31, 2022. The company had no revolver borrowings and $155.3 million of available borrowing capacity.
- Cash flow: Nine-month operating cash flow was $170.7 million, down from $196.8 million, primarily due to increased working capital, including a $38.6 million inventory cash use. Capital expenditures were $5.2 million. Free cash flow is not presented as a company-defined measure in the filing.
- Debt: Gross principal debt was $1.44 billion: $600 million of 3.750% notes due 2031, $400 million of 5.125% notes due 2028 and $440 million of variable-rate term loans due 2028. Net carrying value of long-term debt was $1.424 billion. The company repaid $55 million of term-loan principal during the nine months. No further term-loan payment was required before maturity because optional repayments exceeded required quarterly payments.
- Interest and leverage exposure: Nine-month net interest expense increased to $50.2 million from $48.3 million, as the average borrowing cost rose to 4.5% from 4.1%, despite lower average debt. Approximately $440 million of debt carried variable rates; a 1 percentage-point rate increase would have increased nine-month pre-tax expense and cash flows by about $3.5 million, holding other factors constant.
- Shareholder returns: The company repurchased $50 million of shares under its share repurchase program during the nine months. No common dividends had been declared or paid through December 31, 2022.
Material changes and management commentary
- Quarterly gross margin fell 1.9 percentage points, primarily from higher supply-chain costs and product mix. Pricing actions partly offset cost pressure in North America.
- Advertising and marketing expense declined to $30.4 million from $40.2 million for the quarter, supporting higher contribution margin and operating income despite lower gross profit.
- Nine-month gross profit was nearly flat, while gross margin declined 1.5 percentage points. North American gross profit weakened; International gross profit increased with revenue.
- Management cited inflation, rising interest rates, geopolitical events, supply-chain constraints and pandemic-related uncertainty. It reported no material overall supply-chain disruption to date, but noted product shortages, delays, backorders, shipping challenges, supplier price increases and labor constraints.
- Management expects operating cash flow and existing credit facilities to fund working capital and capital expenditures for the next 12 months, excluding acquisitions. The filing does not provide specific revenue or earnings guidance.
Risks, contingencies and unusual items
- Customer concentration: Walmart represented approximately 19.9% of quarterly and 19.8% of nine-month gross revenue. The five largest brands accounted for 36.9% and 38.7%, respectively, of gross revenue.
- Supply and distribution depend on third parties, including manufacturers and a third-party distribution manager; disruption, labor shortages or supplier price increases could affect availability, cost and results.
- Goodwill and intangible assets are substantial. The company reported no indicators of potential impairment at December 31, 2022, but adverse sales, margin or discount-rate assumptions could lead to future impairment charges.
- Routine legal matters and claims are described; management believes reasonably possible losses, after reserves, will not materially adversely affect the business, financial condition or results.
- The U.S. qualified pension plan settlement process was completed in the first fiscal quarter: plan assets funded lump-sum payments and annuity purchases, with a $0.4 million settlement loss. No additional qualified-plan contributions were required.
- The company was in compliance with applicable debt covenants at December 31, 2022 and anticipated continued compliance in the normal course. Disclosure controls were judged effective, and no material change in internal control was reported for the quarter.
Important facts for investors to verify
- Whether pricing, product mix and cost management can stabilize or restore gross margins as supply, labor and transportation costs evolve.
- Whether North American category softness persists and whether International growth, including Australia, is sustainable.
- Working-capital trends, particularly the increase in inventory, and the company’s ability to sustain operating cash flow while servicing debt and funding buybacks.
- Variable-rate debt exposure, covenant headroom and the availability of the $155.3 million revolver capacity.
- Exposure to major customers, third-party manufacturing and distribution, and possible impairment sensitivity of goodwill and brands.